| Autor: |
Sumarokov AB; Institute of Cardiology of Russian Cardiology Scientific and Production Complex., Buryachkovskaya LI; Federal State Budgetary Institution, 'Russian Cardiology Science and Production Center' of the Ministry of Health of the Russian Federation., Lomakin NV; Federal State Budgetary Institution 'Central Clinical Hospital with Outpatient Clinic' at the Department of Presidential Affairs., Dotsenko YV; Institute of Cardiology of Russian Cardiology Scientific and Production Complex., Uchitel IA; Institute of Cardiology of Russian Cardiology Scientific and Production Complex., Timofeeva LA; Central Clinical Hospital with Policlinic of the Presidential Administration of the Russian Federation. |
| Jazyk: |
ruština |
| Zdroj: |
Kardiologiia [Kardiologiia] 2018 Jan (1), pp. 41-52. |
| DOI: |
10.18087/cardio.2018.1.10081 |
| Abstrakt: |
Optimal duration of dual antiplatelet therapy (DAPT) after stent implantation is uncertain. Some patients have an extended risk of thrombotic complications including that of very late stent thrombosis after cessation of recommended course of DAPT (6-12 months). On the other hand, there is a real risk of bleeding on DAPT. In this review, we present and discuss results of clinical trials of long-term DAPT and data of their meta-analyses. The review also contains consideration of some aspects of new AHA/ACC recommendations (2016) on duration of DAPT. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
